M2 includes a broader set of financial assets held principally by households. M2 consists of M1 plus: (1) savings deposits (which include money market deposit accounts, or MMDAs); (2) small-denomination time deposits (time deposits in amounts of less than $100,000); and (3) balances in retail money market mutual funds (MMMFs). Seasonally adjusted M2 is computed by...
Link to Culper Research report that states they are shorting VBIV because the company is "worthless"
First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make...
It's too early for me to enter into a position here, but as WIN219 mentioned in his recent idea, an obvious Adam and Eve chart pattern is forming. If $2.36 - $2.40 price level holds up and the pattern completes, I will open a long position. This might be a great buy opportunity if the chart plays out.
I've been actively trading the recent VBIV bull run, and I still expect the bull run to continue from now until year's end. However, the stock is up over 100% in a very short time, and this may be the correction to this rapid movement.
I'm not actively trading this idea yet, but I will update the idea if I decide to short.
Remember folks, just ideas!
The NASDAQ-100 Index includes 100 of the largest domestic and international non-financial companies listed on The NASDAQ Stock Market based on market capitalization. The Index reflects companies across major industry groups including computer hardware and software, telecommunications, retail/wholesale trade and biotechnology.
Last week, the...
VBIV is breaking out of a symmetrical triangle on 15min within a much larger ascending triangle on 4hr which may be a continuation pattern off of the local price bottom. I expect to see $1.50 within next 3 trading days.
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020